CHROMADEX CORP (CDXC)

US1710774076 - Common Stock

3.78  +0.02 (+0.53%)

After market: 3.88 +0.1 (+2.65%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CDXC. CDXC was compared to 58 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for CDXC as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, CDXC is valued expensive at the moment.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CDXC has reported negative net income.
CDXC had a positive operating cash flow in the past year.
In the past 5 years CDXC always reported negative net income.
CDXC had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -8.98%, CDXC is in line with its industry, outperforming 48.28% of the companies in the same industry.
CDXC's Return On Equity of -17.35% is in line compared to the rest of the industry. CDXC outperforms 48.28% of its industry peers.
Industry RankSector Rank
ROA -8.98%
ROE -17.35%
ROIC N/A
ROA(3y)-28.83%
ROA(5y)-43.66%
ROE(3y)-53.52%
ROE(5y)-87.83%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CDXC has a Gross Margin of 60.77%. This is amongst the best in the industry. CDXC outperforms 82.76% of its industry peers.
In the last couple of years the Gross Margin of CDXC has grown nicely.
The Profit Margin and Operating Margin are not available for CDXC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.69%
GM growth 5Y3.61%

More info and screens

7

2. Health

2.1 Basic Checks

CDXC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDXC has been increased compared to 1 year ago.
The number of shares outstanding for CDXC has been increased compared to 5 years ago.
CDXC has a better debt/assets ratio than last year.

2.2 Solvency

CDXC has an Altman-Z score of 3.37. This indicates that CDXC is financially healthy and has little risk of bankruptcy at the moment.
CDXC has a Altman-Z score of 3.37. This is in the better half of the industry: CDXC outperforms 62.07% of its industry peers.
The Debt to FCF ratio of CDXC is 0.00, which is an excellent value as it means it would take CDXC, only 0.00 years of fcf income to pay off all of its debts.
CDXC's Debt to FCF ratio of 0.00 is amongst the best of the industry. CDXC outperforms 94.83% of its industry peers.
CDXC has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
CDXC has a better Debt to Equity ratio (0.00) than 75.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.37
ROIC/WACCN/A
WACC12.31%

2.3 Liquidity

CDXC has a Current Ratio of 2.40. This indicates that CDXC is financially healthy and has no problem in meeting its short term obligations.
CDXC has a Current ratio (2.40) which is in line with its industry peers.
A Quick Ratio of 1.70 indicates that CDXC should not have too much problems paying its short term obligations.
The Quick ratio of CDXC (1.70) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 1.7

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 73.08% over the past year.
The Revenue has grown by 16.00% in the past year. This is quite good.
Measured over the past years, CDXC shows a very strong growth in Revenue. The Revenue has been growing by 21.50% on average per year.
EPS 1Y (TTM)73.08%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q100%
Revenue 1Y (TTM)16%
Revenue growth 3Y12.14%
Revenue growth 5Y21.5%
Revenue growth Q2Q0.93%

3.2 Future

CDXC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.30% yearly.
CDXC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.26% yearly.
EPS Next Y80.58%
EPS Next 2Y66.65%
EPS Next 3Y53.3%
EPS Next 5YN/A
Revenue Next Year17.03%
Revenue Next 2Y17.12%
Revenue Next 3Y18.26%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

CDXC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CDXC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of CDXC indicates a somewhat cheap valuation: CDXC is cheaper than 72.41% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 40.85
EV/EBITDA N/A

4.3 Compensation for Growth

CDXC's earnings are expected to grow with 53.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66.65%
EPS Next 3Y53.3%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CDXC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHROMADEX CORP

NASDAQ:CDXC (5/3/2024, 6:43:08 PM)

After market: 3.88 +0.1 (+2.65%)

3.78

+0.02 (+0.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap284.67M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.98%
ROE -17.35%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 60.77%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.52
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.4
Quick Ratio 1.7
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)73.08%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y80.58%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)16%
Revenue growth 3Y12.14%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y